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Diffuse large B-cell lymphoma is the most common malignantlymphoma in adults. By gene-expression profiling, this lym-phoma is divided in three cell-of-origin subtypes with distinct
molecular and clinical features. Most lymphomas arise sporadically, yet
familial clustering is known, suggesting a genetic contribution to disease
risk. Familial lymphoma cases are a valuable tool to investigate risk
genes. We studied a Swiss/Japanese family with 2 sisters affected by a
primary mediastinal B-cell lymphoma and a non-germinal center diffuse
large B-cell lymphoma not otherwise specified, respectively. The somat-
ic landscape of both lymphomas was marked by alterations affecting
multiple components of the JAK-STAT pathway. Consequently, this
pathway was constitutively activated as evidenced by high pJAK2 as
well as increased nuclear pSTAT3 and pSTAT6 in malignant cells.
Potential lymphoma risk variants were identified by whole exome
sequencing of the germline DNA derived from siblings and unaffected
family members. This analysis revealed a pathogenic variant in TIRAP,
an upstream regulator of NF-kB, in both affected siblings and their
mother. We observed increased B-cell proliferation in family members
harboring the TIRAP p.R81C variant. B-cell proliferation correlated with
TIRAP and NF-kB target gene expression, suggesting enhanced NF-kB
pathway activity in TIRAP p.R81C individuals. TIRAP knockdown
reduced B-cell survival and NF-kB target gene expression, particularly in
individuals with TIRAP p.R81C. Functional studies revealed significant-
ly increased NF-kB activity and resistance to stress-induced cell-death
by TIRAP p.R81C. The identification of an inherited TIRAP variant pro-
vides evidence for a novel link between genetic alterations affecting the
NF-kB pathway and lymphomagenesis.
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ABSTRACT
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in
adults.1 Its molecular subtypes, activated B-cell-like (ABC), germinal center B-cell-
like (GCB) DLBCL, and primary mediastinal B-cell lymphoma (PMBL) arise from 
B-cells at distinct differentiation stages.2,3 PMBL is clinically aggressive with bulky
mediastinal masses; it accounts for up to 10% of DLBCLs, and preferentially occurs
in young female patients. 
Next-generation sequencing provided insights in genetic lesions of de novo DLBCL
and its subtypes.4-10 The genetic hallmarks of PBML are amplifications of the 9p24
locus containing JAK2 and PDL1. Present in 70% of PMBL, this amplification is rare
in other DLBCL subtypes.11-13 Constitutive NF-kB pathway activity through various
mechanisms is characteristic of PMBL and ABC-DLBCL.14
Until now, the genetic risk factors for DLBCL/PMBLs have remained obscure.
Population-based studies reported an increased risk for
DLBCL in relatives of individuals with DLBCL, and
genome-wide association studies identified several com-
mon single nucleotide variants associated with sporadic
DLBCL.15-18 Familial clustering provides evidence for
Mendelian susceptibility. In very rare cases, familial aggre-
gation is associated with hereditary cancer syndromes,18
but as far as other syndromes are concerned, a heritable
basis for DLBCL is not fully understood. A germline vari-
ant in MLL described in a Finnish family is still the only
reported variant linked to familial PMBL.19 Although
familial lymphomas account for less than 5% of cases,
these pedigrees are a valuable tool to help identify risk
genes that might also contribute to a better understanding
of more frequent sporadic cases. 
Here, we investigate a Swiss/Japanese family in which 2
out of 3 children were diagnosed with aggressive B-cell
lymphomas arising in the mediastinum. Whole exome
sequencing (WES) on the germline DNA of the affected
siblings and healthy family members identified a variant
in the TIR-domain-containing adaptor protein (TIRAP).
TIRAP engages signals from TLR2 and TLR4 receptors and
recruits MyD88 to the plasma membrane mediated
through Toll/interleukin-1 receptor (TIR) domain interac-
tion.20 Downstream signaling includes activation of 
IL-1R-associated kinases (IRAK), ultimately culminating in
the activation of the transcription factors NF-kB and 
AP-1. In this family, we identified an inherited TIRAP
p.R81C variant in 2 affected siblings. This variant provid-
ed B-cells with increased proliferation and survival
through enhanced NF-kB activity. Functional studies
revealed that TIRAP p.R81C enhanced NF-kB gene signa-
ture and reduced stress-triggered cell death. Collectively,
we provide evidence that TIRAP p.R81C may act as a
novel lymphoma risk variant and our data suggest that
TIRAP should be integrated into the complex network of
genes contributing to deregulated NF-kB signaling
involved in lymphomagenesis. 
Methods
Patients 
Samples from patients, non-affected family members, and
healthy donors were collected after informed consent. This study
was approved by the local ethics committee (KEK-BE116/11) and
was conducted in accordance with the Declaration of Helsinki.
The diagnosis of DLBCL/PMBL was made according to the 2017
World Health Organization classification and pathological review
by SD and AT confirmed the diagnosis.1 Genomic DNA was ex-
tracted from peripheral blood mononuclear cells (PBMCs) using
standard methods. Tumor DNA was isolated from formalin-fixed
paraffin embedded tissues (FFPE) using phenol-chloroform. In
FFPE samples, tumor cell-rich areas were identified on CD20
stained sections and separated from surrounding tissue by laser
microdissection. 
Whole exome sequencing
The quality of extracted DNA was assessed by Bioanalyzer
(Agilent) and a PCR fragment size-based assay developed at
Fasteris (Geneva, Switzerland). Prior to library preparation with
TruSeq DNA Sample Preparation Kit (Illumina), DNA samples
were treated with PreCR Repair Mix (New England Biolabs).
Exome capturing was performed using TruSeq Exome Enrichment
Kit (Illumina) and samples were sequenced on an Illumina
HiSeq2500 instrument with 100bp paired-end reads (Fasteris,
sequencing performed between 2012 and 2014). As the FFPE lym-
phoma sample of sister 2 resulted in a low-yield library of poor
quality, the library preparation was modified: after PreCR Repair
mix treatment, DNA was split, and four libraries were prepared
simultaneously using the Nextera Exome Enrichment Kit
(Illumina). Before exome enrichment, libraries were pooled and
sequencing was performed as described above. Both exome
enrichment kits contained the same set of baits, resulting in iden-
tical exome coverage. Whole exome sequencing (WES) data has
been deposited at the European Nucleotide Archive
(http://www.ebi.ac.uk/ena, accession number PRJEB15254). See
Online Supplementary Table S3 for exome data metrics.
Analysis of germline and somatic variants
Raw sequence read quality was assessed using FastQC. Reads
were mapped to the human reference genome hg19 using Bowtie-
2 v.2.2.1, and duplicated reads were removed by Pi-card-tools
v.1.80. Germline variant calling was performed using the Genome
Analysis Toolkit (GATK v.3.3.0) best practices workflow using
Haplotype Caller and limiting the analysis to enriched targets
±100bp. We used GATK v.3.3.0 to recalibrate the variant quality
and refine the genotypes using population (1000 Genomes Project,
phase 1 data) and pedigree information. Variants in low complex-
ity regions were removed.21 Germline variants were prioritized as
following: 1) good quality genotype in both sisters (Phred quality
≥20); 2) moderate/high impact based on SnpEff v.3.2 prediction; 3)
novel/known variant at frequency of less than 1% (not polymor-
phisms) according to the 1000 Genomes Database and the Exome
Variant Server; and 4) the presence of at least one copy of the puta-
tively harmful allele in both siblings. Only variants not present as
homozygote in healthy family members were selected. Possible
links between genes with germline variants and terms related to
cancer and malignant lymphomas were assessed by Ariadne
Genomics Pathway Studio v.9 (Elsevier). Alterations with a pre-
dicted link to the disease were annotated with PolyPhen-2, SIFT,
MutationTaster and GERP++ effect prediction scores using
dbNSFP v.2.1, and Combined Annotation Dependent Depletion
(CADD) scores v.1.1 (available from https://cadd.
gs.washington.edu/). Pathway Studio was used to identify gene net-
works and canonical pathway enriched for genes containing puta-
tively deleterious variants. The enrichment-scores were calculated
using c2 test comparing genes with putatively deleterious muta-
tions to the proportion of background genes in the Gene Ontology
group. An enrichment-score ≥3 corresponded to a significant link
(P<0.05). See also Online Supplementary Appendix.
Results 
Clinical and histopathological characterization of the
mediastinal B-cell lymphomas
The Swiss/Japanese family investigated includes 2
female siblings with lymphomas (Figure 1). The older sis-
ter 1 developed a PMBL at 30 years of age and died with
primary progressive disease (Online Supplementary Table
S1). At 25 years of age, sister 2 was diagnosed with a stage
IIA non-germinal center (GC) DLBCL, not otherwise spec-
ified (NOS) with a mediastinal mass and cervical lym-
phadenopathy. Chemo-immunotherapy achieved an
ongoing remission. Smoldering myelomas IgGλ were
detected in the father and his monozygotic twin at 65
years of age. Other family members are currently healthy,
and there are no other hematologic malignancies in the
extended family. 
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Both lymphomas lacked evidence of an Epstein-Barr
virus infection (Online Supplementary Table S2), showed a
clear cytoplasm and compartmentalizing sclerosis, and
were CD20, CD30 and Ki-67 positive. However, the GC
markers BCL6, CD10 and GCET1 were only expressed in
the PMBL of sister 1, as was CD23 and BCL2. Despite the
expression of CD30 and sclerosis, the clinical presenta-
tion, morphology and immunophenotype of the tumor in
sister 2 were consistent with a non-GC DLBCL NOS.1
Given its genetic (9p24 and 12q13 gains, SOCS1 and
STAT6mutations), and phenotypic characteristics (expres-
sion of CD30, overexpression of JAK2-STAT-cascade
members), this lymphoma can retrospectively be consid-
ered to most probably represent a PMBL, and was initially
designated as non-GC DLBCL NOS with features of
PMBL. 
Analysis of the coding genome of lymphomas
The somatic landscape of both lymphomas was ana-
lyzed by WES using the Illumina technology on DNA
derived from laser-dissected FFPE tissue sections (Online
Supplementary Methods). Mutations were validated using
Ion Proton sequencing, and their somatic origin was con-
firmed by the absence in matched normal DNA isolated
from PBMCs. A total of 192 and 130 confirmed clonal
protein altering mutations were identified in the lym-
phomas of sisters 1 and 2, respectively (Online
Supplementary Table S7). Most of those mutations were
missense mutations, with a low number of nonsense and
splice site variants (Figure 2A). 
In addition, somatic copy number alterations (CNA)
were analyzed by array comparative genomic hybridiza-
tion (aCGH). While the tumor of sister 1 contained seven
gains and two deletions, three gains were detected in the
lymphoma of sister 2. Interestingly, 9p24 and 12q13 gains
were present in both lymphomas (Figure 2B).
Fluorescence in situ hybridization (FISH) analyses revealed
a trisomy at 8q24 (including MYC) in the lymphoma of
sister 1, in line with the gain on chromosome 8 by aCGH
(Figures 2B and 4B). Taken together, the analysis of CNA
and somatic mutations reflected the known complex
genetic landscape in those entities. The overall number of
somatic lesions in the lymphoma of sister 1 was consid-
erably higher (Figure 2C). 
The JAK-STAT pathway has somatic mutations in 
multiple genes and is constitutively active
As mentioned above, aCGH revealed a 9p24 gain in
both lymphomas (Figure 3A). The amplification of JAK2,
a key target of the 9p24 gain, in both tumors was con-
firmed by FISH (Figure 3B). Moreover, a gain of 12q13
encompassing STAT2 and STAT6, was detected in both
lymphomas (Figure 3C). Besides CNA, we also identified
somatic mutations in key genes of the JAK-STAT path-
way. Each tumor harbored a private missense mutation
within the DNA binding domain of STAT6 (Figure 3D). In
addition, SOCS1, encoding a negative regulator of the
JAK-STAT pathway, was mutated in the lymphoma of sis-
ter 1 (Figure 4A). Collectively, these somatic alterations
caused constitutive activation of the JAK-STAT pathway
as evidenced by high cytoplasmic expression of phospho-
rylated JAK2 (pJAK2) and increased nuclear pSTAT3 and
pSTAT6 expression in most tumor cells (Figure 3E). In
summary, despite distinct pathological and clinical fea-
tures, these data revealed a shared aberrant activation of
JAK-STAT signaling which is a known signature in
PMBL.10,22,23 
Genetic alterations related to the distinct clinical 
outcome
In contrast to ABC- and GCB-DLBCL, PMBLs have a
favorable prognosis when responding to chemo-
immunotherapy.2 To investigate genetic lesions associated
with the different clinical outcome, we focused on genes
with a reported pathogenic role in lymphomas and/or
genes which were mutated in more than 10% of
DLBCLs.4-10 Mutations in B2M, and TP53, REL and MYC
gains as well as a CIITA break apart were confined to the
PMBL of sister 1 who died of primary progressive disease
(Figure 4A and B). Although amplification of PDL1 result-
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Figure 1. Mediastinal B-cell lym-
phomas arising in 2 female siblings.
Pedigree of the Swiss/Japanese fam-
ily under study. Circles and squares
represent female and male family
members, respectively. Open symbols
indicate unaffected persons; closed
symbols repre-sent the 2 siblings
affected by primary mediastinal B-cell
lymphoma (PBML) and mediastinal
non-germinal center (GC) diffuse
large B-cell lymphoma (DLBCL), not
otherwise specified (NOS), respec-
tively. The deceased individual (sister
1) is marked by a slash through the
symbol. The year of diagnosis is
shown in brackets and the year of
birth is denoted by *. Both lym-
phomas were classified according to
the World Health Organization 2017
classification.1
ing from the 9p24 gain (Figure 4A) is a common feature of
both lymphomas, PDL1 was only expressed on the malig-
nant B-cells of sister 1 (Figure 4B). 
The co-occurrence of genetic alterations involving genes
related to immune-cell crosstalk in the lymphoma of sister
1 involving PDL1 expression, B2M p.M1R mutation and
genomic alterations of CIITA are an interesting finding
that suggests a combined role in escape from immune-sur-
veillance.24,25 In summary, we identified genetic lesions
that may collectively contribute to the distinct clinical out-
come. Of note, TP53 mutations, MYC gains, CIITA
translocation and expression of PDL1 on malignant B cells,
all solely present in the lymphoma of sister 1, have been
associated with an inferior overall and progression-free
survival in DLBCL.26-29 BCL2 expression, as observed in the
lymphoma of sister 1, in the absence of a translocation
(Online Supplementary Table S2) has a controversial prog-
nostic role.30
Whole exome sequencing identified lymphoma risk
genes 
The low age- and gender-adjusted incidence rate for
sporadic DLBCL (0.1/100,000 cases in Switzerland31), and
the occurrence of 2 siblings affected by mediastinal B-cell
lymphomas suggested a genetic predisposition for lym-
phomagenesis in this family. Therefore, we performed
WES on DNA from PBMCs of both sisters and all the
other members of the core family (Figure 1). A total of 547
rare protein altering variants in 444 genes were identified
out of 86,000 screened variants in the germline DNA of
each sister. After excluding variants that were present as
homozygote in unaffected family members, 274 variants
in 234 genes remained. To find a potential link between
those 234 candidate genes and deregulated proliferation,
we performed a comprehensive gene ontology and path-
way enrichment analysis. The result indicated a signifi-
cant link between 45 of these candidate genes with cancer
and/or malignant lymphoma. To identify potential delete-
rious alterations, the pathogenicity of variants in those 45
cancer related genes was examined by five different in sil-
ico algorithms. At the end, 15 variants in 15 candidate
genes were predicted as deleterious by all algorithms and
were considered for further analyses (Online Supplementary
Figure S1A). Mutated genes were significantly enriched in
processes like proliferation, lymphocyte activation and
response to DNA damage, all pathways crucial for tumori-
genesis (Online Supplementary Figure S1B). Of note, MLL
the only PMBL/DLBCL susceptibility gene reported so far
was not found to harbor variants in this family.19
Interestingly, we identified TIRAP among those candi-
dates. TIRAP is an adapter protein that engages signals
from TLR2 and 4 and thereby activates the NF-kB path-
TIRAP, a novel familial lymphoma risk gene
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Figure 2. Overall load of numerical and structural genomic alterations in the lymphomas of both siblings. (A) Number (N.) of all validated (by IonProton sequencing)
non-silent somatic clonal mutations identified through whole exome sequencing in the two tumors. (B) Chromosomal gains and losses detected in the two lymphomas
by array comparative genomic hybridization (aCGH). In the aCGH profiles, the normalized log2 ratios are plotted based on their chromosome position, with vertical
bars separating the chromosomes. Regions with losses and gains are represented by decreased and increased log2 ratios, respectively. Genomic changes are
marked in red (gain) and green (loss). Copy number (CN) alterations that are present in both tumors are underlined. (C) Combined load of somatic non-silent muta-
tions as well as CN gains and losses identified in the two investigated lymphomas.
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way. Dysregulation of the NF-kB pathway is the onco-
genic hallmark of ABC-DLBCL and PMBL.14 Of note, in
420 primary DLBCLs, high TIRAP expression correlated
with poor survival and was significantly increased in high
risk patients (data generated by SurvExpress32) (Online
Supplementary Figure S2A). Besides, amplifications of 11q
and 11q24 which also contain TIRAP, have been reported
in approximately 20% of DLBCLs and PMBLs.11,33,34
Somatic TIRAP mutations occurring in various cancers
including DLBCL are listed in COSMIC and genomic
sequencing studies on several hundred DLBCLs revealed
somatic alterations in TIRAP in roughly 0.5% of cases.34,35
However, the role of TIRAP in tumorigenesis has so far
not been investigated. Hence, we functionally investigate
whether the identified TIRAP variant in this family con-
tributes to lymphomagenesis. 
TIRAP p.R81C variant is a potential novel risk factor
for lymphomas 
Whole exome sequencing revealed a heterozygous vari-
ant within the coding exon 5 of TIRAP (c.241C>T) in both
sisters and their Japanese mother. The variant was absent
R. Burkhard et al.
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Figure 3. The JAK-STAT pathway has somatic mutations in multiple genes and is constitutively active. (A) aCGH probe view of the 9p24 gain. A duplication of the
JAK2 locus was detected in both samples, shown as an increase of the average log2 ratio above zero (bold line). Shaded area indicated the extent of a copy number
aberration. (B) Fluorescence in situ hybridization (FISH) signals with BAC probes for the 5’ and 3’ regions of JAK2. Arrows indicate examples of cells with multiple
FISH signals. Note green autofluorescent sclerosing bundles in the background. Scale bars: 10 mm. (C) Array comparative genomic hybridization (aCGH) probe view
of gains in 12p13 region, which among other genes also affect STAT2 and STAT6 as indicated by arrows. (D) (Top) Schematic representation of the human STAT6
gene locus with open and closed boxes indicating non-coding and coding exons, respectively. (Bottom) Confirmed somatic missense mutations located within the
DNA binding domain of STAT6. Protein domain annotation according to Pfam. (E) The expression of phosphorylated (p) pJAK2, pSTAT3 and pSTAT6 in the two lym-
phomas was assessed by immunohistochemistry. Scale bars: 10 mm.
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in other unaffected family members (Figure 5A). This vari-
ant resulted in a substitution of the arginine at amino acid
residue 81 to a cysteine (p.R81C) which is highly con-
served among species and located in close proximity to
the functional TIR domain (Online Supplementary Figure
S2B and C). The TIRAP p.R81C variant was predicted to
be deleterious by five out of five applied algorithms
(Online Supplementary Figure S2D), has a dbSNP identifier
(rs138228187) and is reported in COSMIC. It has a global
minor allele frequency of 0.00006 and 0.0006 in ExAC and
1000 Genomes, respectively, and 0.0005 in the Japanese
population, and is therefore not a polymorphism.36,37
Sanger sequencing of cDNA derived from fresh PBMCs of
the family members confirmed the TIRAP p.R81C status
and expression of the variant allele in sister 2 and her
mother (Figure 5A and Online Supplementary Figure S3). Of
note, the p.R81C variant was also identified in the lym-
phomas of both siblings (data not shown).
To investigate the functional consequence of TIRAP
p.R81C, we assessed the expression of pIRAK1 and total
IRAK4, two downstream kinases and activators of the NF-
kB signaling pathway. For IRAK4, our analysis was con-
fined to the total protein, as an antibody to reliably deter-
mine its phosphorylated form on FFPE tissue was not
available. GC B-cells of healthy controls showed little to
no pIRAK1 and IRAK4 expression whereas p.R81C TIRAP
carrying malignant B-cells of both sisters were clearly pos-
itive for these markers (Figure 5B and C). This suggests
that the TIRAP downstream signaling is predominantly
active in malignant B-cells with the p.R81C mutation. The
relevance of this pathway is underlined by the analysis of
36 primary ABC-DLBCLs that revealed that 63% and 17%
expressed pIRAK1 and IRAK4, respectively (Figure 5C).
GCB-DLBCLs, however, generally lacked the expression
of both kinases. 
To assess TIRAP/NF-kB pathway activity in non-malig-
nant cells, we determined the gene expression of TIRAP as
well as genes involved in cell proliferation and survival,
among them several targets of NF-kB in PBMCs of living
family members. Unsupervised hierarchical clustering
analysis revealed two clusters, separating TIRAP p.R81C
and wild-type (WT) samples based on the expression sig-
nature of selected genes (Figure 5D). PBMCs carrying the
TIRAP p.R81C mutation expressed higher levels of TIRAP
as well as genes involved in cell survival, cell cycle and
proliferation. In contrast, TIRAP WT PBMCs showed
higher expression of CASP9, which is implicated in intrin-
sic apoptosis. 
Next, we studied the impact of TIRAP p.R81C on pri-
mary B-cells. An increase in proliferating B-cells as deter-
TIRAP, a novel familial lymphoma risk gene
haematologica | 2019; 104(4) 771
Figure 4. Genetic alterations related to the different clinical outcome. (A) Comparison of the somatic landscape in the two lymphomas implementing the lesions
identified by whole exome sequencing, array comparative genomic hybridization (aCGH) and fluorescence in situ hybridization (FISH). Only alterations in genes which
are present in more than 10% of diffuse large B-cell lymphoma (DLBCL) cases and/or with a pathogenic significance in lymphoid malignancies were considered for
this comparison.4-10 Mutations (M), copy number alterations (CN) and translocations (Tx) are sorted according to whether they were found to be mutated in both
tumors or restricted to one lymphoma only. Numbers indicate the total amount of identified somatic mutations. In red, genes which have been associated with worse
clinical outcome.9,26-29 (B) (Left) Representative FISH signal patterns using MYC and CIITA break apart assay in the primary mediastinal B-cell lymphoma (PMBL) of
sister 1. Arrows indicate examples of cells with MYC (multiple FISH signals) gains and CIITA break apart (split red and green FISH signals), respectively. Scale bars:
10 mm. (Right) Immunohistochemistry analysis of PDL1 protein expression in the lymphoma of sister 1. Scale bar: 50 mm. 
A
B
R. Burkhard et al.
772 haematologica | 2019; 104(4)
Figure 5. TIRAP p.R81C a potential novel familial lymphoma risk variant. (A) (Top) Schematic representation of the human TIRAP gene locus with open and closed
boxes indicating non-coding and coding exons, respectively. (Bottom) Whole exome sequencing data for the affected region of the TIRAP exon 5 visualized in integra-
tive genomic viewer demonstrating a heterozygous variant in both sisters and their mother, whereas homozygous wild-type (WT) sequence was observed in the
remaining family members. Sanger sequence data of complementary (c) DNA isolated from fresh peripheral blood mononuclear cells (PBMCs) showing the same
variant. Of note, no cDNA was available for sister 1 (deceased). (B) IRAK1 phosphorylation (p) and total IRAK4 expression was assessed by immunohistochemistry
(IHC) in the two lymphomas as well as lymphoid tissue of (unmatched) healthy controls. Scale bars: 50 mm. (C) Representation of the percentage of cells expressing
pIRAK1 and total IRAK4 in samples described in (B) as well as 36 activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCLs) and 32 germinal center B-cell-
like diffuse large B-cell lymphoma (GCB-DLBCLs). The primary samples have been described previously.50 (D) Heatmap showing hierarchical clustering of mRNA levels
of genes involved in NF-κB pathway, cell survival and proliferation in peripheral blood mononuclear cells (PBMCs) of mother (M), sister 2 (S2), brother (B) and father
(F). The hierarchical cluster analysis (Euclidean’s method) reveals two major clusters representing TIRAP p.R81C mutated and WT individuals. Bar chart showing the
log2 fold difference in gene expression in TIRAP p.R81C versus WT family members. (E) PBMCs isolated from family members and age- and gender-matched healthy
donors (HD) were cultured in the presence (+) or absence (-) of lipopolysaccharide (LPS) for 12 hours. Ki-67 was measured by flow cytometry on CD20+ B-cells. (F)
Linear correlation (Pearson correlation) between Ki-67+ B-cells and BCL2L1 (left), NFKB1 (right) or TIRAP (below) expression in PBMCs as measured by flow cytometry
and quantitative PCR (normalized to ACTb), respectively.
A B
D
E
F
C
mined by Ki-67 was observed in TIRAP p.R81C com-
pared to TIRAP WT family members (Figure 5E). This
was a surprising finding since circulating B-cells are gen-
erally quiescent,38,39 which we observed in age- and gen-
der-matched healthy individuals as well as TIRAP WT
family members. Sanger sequencing confirmed the
absence of TIRAP p.R81C variant in healthy donors
(Online Supplementary Figure S3). Activation of TLR
through lipopolysaccharide (LPS) further enhanced B-cell
proliferation, preferentially in TIRAP p.R81C individuals
(Figure 5E). The higher level of assessed B-cell prolifera-
tion in TIRAP p.R81C cases was positively correlated
with the increased gene expression levels of TIRAP, as
well as BCL2L1 and NFKB1, as main regulators of NF-kB
signaling in PBMCs of all family members (Figure 5F).
Collectively, our data indicate a potential role of p.R81C
TIRAP, a novel familial lymphoma risk gene
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Figure 6. NF-kB signaling mediated by TIRAP is important for B-cell survival. (A) Peripheral blood mononuclear cells (PBMCs) were isolated from family members
and transfected with control (CTRL) or TIRAP-directed siRNA. Twenty-four hours following transfection, cell viability of CD20+ B-cells was assessed by Annexin V/DAPI
staining and flow cytometry analysis. A representative flow cytometry dot plot and quantification of living B-cells are shown in (A) and (B), respectively. Student 
t-test, *P<0.05. (C) Heatmap showing hierarchical clustering of mRNA levels of genes involved in NF-kB pathway, cell survival and proliferation in PBMCs of mother
(M), sister 2 (S2), brother (B) and father (F) treated as described in (A). Data were clustered using standard Euclidean’s method based on the average linkage. (D)
Bar chart showing the relative expression levels of NFKB1, CASP9, IL6 and MYC genes normalized to ACTb in family members with wild-type (WT) (brother and father)
and p.R81C (sister 2 and mother) TIRAP. Dots represent values of each individual of the investigated family. (E) The difference of gene expression in cells transfected
with TIRAP or CTRL siRNA was calculated from the mean values shown (D). 
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Figure 7. TIRAP p.R81C enhances NF-kB activity and protects against stress-induced
apoptosis. 293T cells were transfected with TIRAP WT-GFP, TIRAP p.R81C-GFP or empty
vector (EV)-GFP plasmids. Twenty-four hours (h) post transfection, 293T cells were FACS
purified for GFP-positive cells. (A) Heatmap showing hierarchical clustering of mRNA lev-
els of six selected genes involved in NF-kB pathway, cell survival and proliferation within
GFP-positive 293T cells. Bar chart showing the log2 fold difference of gene expression
in transfected 293T cells (TIRAP p.R81C or WT vs. EV) of a representative experiment.
(B) FACS purified GFP-positive 293T were cultured in starvation medium for 48 h, and
cell viability was assessed by flow cytometry. Bar chart (mean±Standard Error of Mean)
show percentage of viable cells (AnnexinV– and Viability dye–) of 2 independent experi-
ments performed in replicates. One-way ANOVA with Bonferroni post hoc test was used,
***P<0.001.
A
B
variant in activating NF-kB leading to enhanced B-cell
proliferation and survival.
INF-kB signaling mediated by TIRAP is important for 
B-cell survival
To study the effect of TIRAP on cell survival, we per-
formed a siRNA-mediated knockdown of endogenous
TIRAP in PBMCs isolated from available family members.
Overall, TIRAP knockdown efficiency was 60% at the
mRNA level (Online Supplementary Figure S4A). TIRAP
knockdown significantly diminished the number of living
B-cells (Figure 6A and B). This effect was independent of
the p.R81C, indicating that TIRAP is an important deter-
minant for B-cell survival. Furthermore, we profiled the
expression of genes important for cell survival and prolif-
eration including NF-kB target genes (Figure 6C). Silencing
TIRAP strongly reduced the expression of the NF-kB target
genes (NFKB1, IL6 and MYC) in PBMCs, indicating that
both WT and p.R81C TIRAP mediate signal through the
NF-kB pathway (Figure 6D and Online Supplementary
Figure S4). However, downregulation of NF-kB target
genes was more pronounced in TIRAP p.R81C PBMCs
suggesting that these cells particularly rely on the NF-kB
pathway (Figure 6E and Online Supplementary Figure S4).
Consistent with the reduced B-cell survival, CASP9
expression increased following TIRAP silencing in PBMCs
to a higher extent in p.R81C mutated cells (Figure 6D and
E). Interestingly, NF-kB signature was further reduced fol-
lowing stimulation with LPS (Online Supplementary Figure
S5), supporting the concept that TIRAP transduces signals
from TLR4.20
TIRAP p.R81C drives NF-kB pathway activity and
reduces stress-induced cell death
To evaluate the functional consequence of TIRAP
p.R81C, 293T cells were transfected with bidirectional
plasmids encoding for EGFP and TIRAP p.R81C, TIRAP
WT or empty vector (control), respectively. Under home-
ostatic conditions, we did not observe any changes in cell
viability 24 hours (h) post transfection (Online
Supplementary Figure S6). However, gene expression analy-
sis on GFP-positive transfected cells revealed increased
expression of the NF-kB target genes NFKB1, BCL2L1,
CDKN2A and MYC by TIRAP p.R81C compared to WT
(Figure 7A). Thus, we tested whether these transcriptional
changes could affect cell viability upon stress-induced
challenge. Therefore, sorted GFP-positive cells were cul-
tured in minimal starving media for 48 h. Surprisingly, cell
viability was significantly reduced in control or TIRAP
WT transfected cells (Figure 7B). Remarkably, our data
indicate that TIRAP p.R81C variant is an upstream activa-
tor of NF-kB which leads to a better cell survival/prolifer-
ation via enhanced NF-kB activity and decreased stress-
induced cell death.
Discussion
The etiology of DLBCL is poorly understood. Familial
clustering of lymphoma is reported to increase disease
risk, indicating a role for genetic factors.15,16 Although
familial lymphoma cases are rare, studying such pedigrees
might identify disease-causing variations and lead to a bet-
ter understanding of lymphomagenesis. A Finnish family
with 3 siblings affected by PMBL and a cousin with extra-
nodal DLBCL has been described.19 These lymphomas
segregate with the p.H1845N mutation in MLL. The role
of this variant in lymphomagenesis has not been corrobo-
rated by functional studies, and it is to the best of our
knowledge the only DLBCL/PMBL predisposing mutation
that has been described so far. 
Here, we studied a Swiss/Japanese family with 2 sisters
affected by B-cell lymphomas in the mediastinum.
Although at initial diagnosis their lymphomas were con-
sidered, according to the current WHO classification,1 as
distinct DLBCL subtypes, the characterization of the
somatic lesions by WES and aCGH revealed noticeable
molecular similarities. Their somatic landscape is marked
by multiple alterations affecting important players of the
JAK-STAT signaling cascade which collectively lead to
constitutive pathway activity, known to be crucially
implicated in lymphomagenesis.14 Shared gains of
9p24/JAK2 and 12q13 (STAT2 and STAT6) were detected
by aCGH. Furthermore, we identified missense hotspot
mutations in STAT6 in both lymphomas (p.N417 and
p.D417). A significant enrichment of STAT6 mutations in
PMBL has been described, with mutations being present
in more than 30% of cases.9,22 9p24/JAK2 gains are also
recurrent genetic alterations in PMBL, but are not strictly
confined to this subtype.13,40
Constitutive activation of the NF-kB pathway is a hall-
mark of both ABC-DLBCL and PMBL, and promotes sur-
vival of malignant cells. Somatic oncogenic mutations in
components of the B-cell receptor signaling pathways
including CD79A/B and CARD11 activate NF-kB.14 Gain-
of-function mutations in MYD88 have been described in
29% of ABC-DLBCLs.14 Moreover, TNFAIP3, which nega-
tively regulates the NF-kB pathway, is somatically inacti-
vated in one-third of ABC-DLBCLs and PMBLs.14
Interestingly, germline mutation in TNFAIP3 and CARD11
have been described in lymphomas complicating primary
Sjögren syndrome and congenital B-cell lymphocytosis,
respectively.41,42 We searched for possible risk alleles asso-
ciated with the lymphomas in the family investigated by
WES, and discovered germline variants in TIRAP and
IL1R1 (detailed data on IL1R1 not shown). The latter was not
among the final candidate genes, as the homozygous
mutation was present in all family members.
Nevertheless, the presence of germline variants in two
upstream regulators of NF-kB in a PMBL family is an inter-
esting finding that confirms the importance of the path-
way in lymphogenesis. Of note, our data support the co-
operation between rare germline variants and constitutive
pathway activation in malignant lymphomas.43
The predicted damaging effect of TIRAP p.R81C variant
occurred at a highly conserved amino acid in close prox-
imity to the functional TIR domain that is stabilized by
two internal disulfide bonds.44,45 Therefore the substitution
of an arginine by a cysteine might have implications on
the TIRAP protein interaction with downstream signaling
proteins. Of note, an arginine to cysteine mutation in
MYD88, another adapter molecule involved in NF-kB 
signaling, diminished its interaction with TIRAP.46
In mice, deletion of Tirap reduced B-cell proliferation in
response to TLR4 signaling.20 In agreement with this, we
observed a direct correlation between B-cell proliferation
and TIRAP expression. In this family, a high expression of
TIRAP correlated with the p.R81C genotype. In 420 pri-
mary DLBLC cases, high TIRAP levels correlated with a
poor survival and were significantly increased in high-risk
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DLBCLs.32,47 Furthermore, we linked the enhanced prolif-
eration of TIRAP p.R81C B cells with an increased expres-
sion of NF-kB target genes and genes involved in cell sur-
vival and proliferation in PBMCs. In this context, it is
important to stress that we determined the lymphocytes
to account for more than 65% of cells in the PMBC sam-
ples analyzed. In addition, TIRAP knockdown was paral-
leled by a significant decrease in the gene expression sig-
nature of the NF-kB pathway, particularly in PBMCs car-
rying the p.R81C variant. In contrast, overexpression of
TIRAP p.R81C increased NF-kB gene signature in vitro.
Moreover, TIRAP p.R81C-expressing cells showed
enhanced resistance to stress-induced apoptosis, indicat-
ing that TIRAP p.R81C provides a survival advantage
under those conditions.
Our data link TIRAP p.R81C variant/expression with
increased B-cell proliferation as well as survival, and thus
add TIRAP to the existing network of lymphoma risk
genes that are associated with deregulated NF-kB signal-
ing such as TNFAIP3, CD79A/B, MYD88 and CARD11.
Interestingly, all these genes were unmutated in the lym-
phomas of both sisters. Similar to patients expressing the
oncogenic p.L265P MYD88 variant, patients with aberrant
TIRAP signaling might benefit from IRAK4-selective
kinase inhibitors.48
Diffuse large B-cell lymphoma is a polygenic disease
with a complex pathogenesis. Therefore, additional alter-
ations are required for the full malignant transformation of
B-cells. Interestingly, all the family members investigated
were found to have a homozygous germline loss of
GSTT1, a reported risk factor for lymphomas (Online
Supplementary Figure S7).18 One can hypothesize that the
interplay of the germline TIRAP p.R81C variant and
GSTT1 loss coupled with additional genomic changes cul-
minated in B-cell transformation in the investigated fami-
ly. The identification of the TIRAP p.R81C variant in a
family with mixed ethnic background, along with the
demonstration of distinct targets of recurrent mutations in
Chinese DLBCLs,49 might be an important additional
aspect.
Overall, our findings revealed TIRAP p.R81C to be a
potential lymphoma risk variant in a family of mixed eth-
nic background. Our analysis complements the existing
view on the different players of the NF-kB pathway cru-
cially involved in DLBCL. 
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